List of Excipients in Branded Drug BENZTROPINE MESYLATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn	BENZTROPINE MESYLATE	benztropine mesylate	17478-012	SODIUM CHLORIDE
Akorn	BENZTROPINE MESYLATE	benztropine mesylate	17478-012	WATER
TYA Pharmaceuticals	BENZTROPINE MESYLATE	benztropine mesylate	64725-0012	SODIUM CHLORIDE
TYA Pharmaceuticals	BENZTROPINE MESYLATE	benztropine mesylate	64725-0012	WATER

Generic Drugs Containing BENZTROPINE MESYLATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	benztropine mesylate	0143-9233	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	benztropine mesylate	0143-9233	WATER
Hikma Pharmaceuticals USA Inc	benztropine mesylate	0143-9729	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	benztropine mesylate	0143-9729	WATER
Endo USA Inc	benztropine mesylate	0603-2433	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE

What are the Most Frequently-Used Excipients in BENZTROPINE MESYLATE?

# Of NDCs	Excipient
25	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
33	ANHYDROUS LACTOSE
2	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
11	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
74	CELLULOSE, MICROCRYSTALLINE

Benztropine Mesylate Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Benztropine mesylate is an old, generic anticholinergic drug used primarily for drug-induced extrapyramidal reactions and as an adjunct in parkinsonism. Its commercial opportunity is not based on patent exclusivity. It lies in reliable supply, differentiated dosage forms, hospital-use packaging, excipient tolerability, and improved administration for patients who have difficulty swallowing or require rapid treatment.

The strongest near-term product concepts are:

1. A robust, low-cost immediate-release tablet with a documented excipient profile.
2. A preservative-free, unit-dose injectable presentation for hospital and emergency use.
3. An orally disintegrating tablet or low-volume oral liquid for patients with dysphagia.
4. A formulation designed for excipient-sensitive populations, including lactose-free and low-sodium variants.
5. Regional products adapted to local regulatory requirements and procurement channels.

What dosage forms and strengths are available for benztropine mesylate?

Benztropine mesylate is marketed mainly as immediate-release tablets and an injectable solution.

Dosage form	Common strength or concentration	Primary use	Commercial relevance
Immediate-release tablet	0.5 mg, 1 mg, 2 mg	Maintenance treatment and outpatient use	Lowest-cost generic opportunity
Injection	1 mg/mL	Acute drug-induced extrapyramidal reactions and selected hospital use	Higher manufacturing and packaging requirements
Oral liquid	Not broadly established as a standard U.S. commercial product	Patients unable to swallow tablets	Formulation-development opportunity
Orally disintegrating tablet	Not a standard widely marketed presentation	Dysphagia and assisted administration	Differentiated 505(b)(2) or generic strategy
Extended-release product	No established mainstream product	Not a current commercial standard	Higher development risk and limited clinical rationale

The reference product, Cogentin, has historically been supplied as tablets and injection. Current U.S. generic products are governed through FDA-approved labeling and inactive-ingredient requirements listed in the FDA Inactive Ingredient Database (FDA, n.d.-b; DailyMed, n.d.-a).

Benztropine mesylate is generally used at low milligram strengths. That creates a content-uniformity challenge because the active pharmaceutical ingredient can represent a small fraction of total tablet weight. Blend uniformity, segregation control, and assay precision are more important than tablet mass alone.

What excipients are used in benztropine mesylate tablets?

Existing tablet products commonly use conventional excipient systems such as lactose or another diluent, starch or a disintegrant, talc, and magnesium stearate. Exact compositions vary by manufacturer and presentation. The product label and FDA inactive-ingredient records control the acceptable excipient profile for a specific product (DailyMed, n.d.-b; FDA, n.d.-b).

A conventional immediate-release tablet may include:

• A diluent such as lactose monohydrate, microcrystalline cellulose, or dibasic calcium phosphate.
• A disintegrant such as pregelatinized starch, sodium starch glycolate, crospovidone, or croscarmellose sodium.
• A binder such as povidone or pregelatinized starch.
• A glidant such as colloidal silicon dioxide.
• A lubricant such as magnesium stearate or sodium stearyl fumarate.
• A colorant or film-coating system where needed for product identification.

The preferred excipient strategy depends on the intended commercial position.

Low-cost conventional tablet

For a price-sensitive generic, lactose, starch, talc, and magnesium stearate can support a familiar manufacturing process and a low bill of materials. The main risks are:

• Variable flow in a low-dose blend.
• Overlubrication, which can slow disintegration and dissolution.
• Segregation during transfer and compression.
• Product differentiation limits if the formulation closely resembles existing competitors.

A direct-compression system using microcrystalline cellulose and a modern superdisintegrant may provide better process control, but it can increase raw-material cost.

Lactose-free tablet

A lactose-free formulation can target patients with lactose intolerance and institutional buyers seeking fewer excipient restrictions. Microcrystalline cellulose, mannitol, or dibasic calcium phosphate can replace lactose. Mannitol can improve mouthfeel and support an orally disintegrating presentation, but it may increase tablet friability or create compression and moisture-management issues.

Dye-free and low-excipient tablet

A dye-free tablet can simplify labeling and reduce concern among patients with sensitivity to certain colorants. A minimal formulation using a filler, disintegrant, and lubricant can support a clean-label position. The commercial value is limited unless combined with a meaningful delivery advantage, such as an orally disintegrating dosage form or a tablet designed for institutional use.

How should the excipient system address benztropine mesylate stability?

The excipient system should be selected through compatibility, accelerated stability, dissolution, and moisture-sorption studies. Benztropine mesylate is an amine-containing salt, so the development program should evaluate moisture, pH-dependent behavior, and interaction with reactive excipients.

Key compatibility issues include:

• Reducing sugars such as lactose, which can create Maillard-type reactions with amine-containing drugs under certain conditions.
• Excessive moisture, which can affect powder flow, tablet hardness, and chemical stability.
• Alkaline microenvironments, which may alter the salt form or dissolution behavior.
• High lubricant levels, which can reduce wetting and slow release.
• Reactive impurities in cellulose, starch, or coating materials.
• Container interaction, particularly in liquid and injectable products.

Lactose may remain commercially acceptable when supported by compatibility and stability data, but a lactose-free formulation can reduce one development risk and create a differentiated label. The decision should be based on actual impurity growth, dissolution, and shelf-life performance rather than on an assumption that lactose is unsuitable.

The target for an immediate-release tablet should be rapid and consistent release across the proposed shelf life. The formulation should be tested under long-term and accelerated conditions using assay, related substances, dissolution, water content, hardness, friability, and disintegration methods appropriate to the product.

What injectable excipients are appropriate for benztropine mesylate?

The injectable product has a different commercial and regulatory profile from the tablet. The formulation must address sterility, particulate matter, container closure, pH, tonicity, extractables and leachables, and compatibility with administration equipment.

A basic injectable system may use:

• Water for Injection.
• Sodium chloride or another tonicity agent.
• A pH adjustment system, if required.
• No preservative for a single-dose presentation.

A preservative-free, single-dose ampoule or vial is commercially attractive for hospitals because it reduces preservative exposure and simplifies compatibility with vulnerable patient populations. The tradeoff is higher packaging cost and stricter aseptic processing controls.

A multidose preserved product may reduce packaging cost per dose, but it introduces preservative compatibility, microbial effectiveness, labeling, and institutional-use considerations. The choice should be driven by the target channel:

Injectable strategy	Advantages	Main risks
Preservative-free single-dose vial	Broad hospital acceptability and simple labeling	Higher unit cost and aseptic manufacturing burden
Preservative-free ampoule	Low extractables and established emergency-use format	Breakage, glass particles, manual opening
Prefilled syringe	Faster administration and reduced preparation steps	Device development, siliconization, extractables, higher cost
Multidose vial	Lower packaging cost per dose	Preservative and in-use stability requirements
Ready-to-use small-volume bag or syringe	Workflow differentiation	More complex stability and device validation

The injectable formulation should not use an excipient solely for marketing differentiation. Every additional component increases the analytical, toxicological, and regulatory burden.

What commercial opportunities exist for benztropine mesylate?

1. Hospital-focused injectable supply

The most direct commercial opportunity is a dependable injectable product for hospitals, emergency departments, psychiatric facilities, and long-term-care institutions. Procurement decisions often emphasize supply continuity, unit cost, packaging reliability, and shortage resilience.

Potential product advantages include:

• Preservative-free single-dose packaging.
• Terminal sterilization where feasible, or a validated aseptic process.
• Clear labeling of concentration and route.
• Barcoding compatible with hospital medication systems.
• Low-breakage packaging.
• Consistent availability in contract-manufacturing and wholesaler channels.

The injectable market is likely more sensitive to manufacturing interruptions than the tablet market because sterile production has fewer qualified manufacturing sites and higher validation requirements.

2. Orally disintegrating tablet

An orally disintegrating tablet could address patients with dysphagia, psychiatric illness, parkinsonism, or limited access to water. Mannitol, crospovidone, croscarmellose sodium, and suitable taste-masking agents could support rapid dispersion.

Development issues include:

• Bitter or unpleasant taste.
• Low-dose content uniformity.
• Mechanical fragility.
• Packaging protection against moisture.
• Requirement to demonstrate rapid disintegration and acceptable dissolution.
• Potentially higher unit cost than a conventional tablet.

A blister package with high moisture barrier protection would likely be more suitable than a standard high-density polyethylene bottle if the formulation is moisture-sensitive or mechanically fragile.

3. Oral liquid

An oral liquid could serve patients who cannot swallow tablets and facilities that require dose flexibility. The formulation must control:

• Solubility or uniform suspension behavior.
• pH.
• Preservative effectiveness.
• Microbial limits.
• Dose-measurement accuracy.
• Chemical stability after opening.
• Palatability.

A solution is preferable if the active salt remains sufficiently soluble across the intended concentration and pH range. If not, a suspension may be required, with wetting agents, suspending agents, and redispersibility controls.

A liquid product could be commercially useful in long-term-care and pediatric-adjacent settings, but the approved indication, dosing population, and anticholinergic safety profile limit the size of the opportunity. Benztropine is not a broad pediatric consumer product.

4. Excipient-sensitive formulation

A lactose-free, dye-free, gluten-free-labeled, or low-sodium product may appeal to institutional formularies and patients with specific excipient concerns. These attributes rarely justify a premium by themselves. They become more commercially relevant when paired with reliable supply, a clear package insert, and a differentiated dosage form.

5. Contract and private-label supply

Because benztropine mesylate is an established generic, manufacturers may pursue:

• Private-label tablets for regional wholesalers.
• Institutional contracts.
• Hospital-system supply agreements.
• Dual-source manufacturing arrangements.
• Geographic licensing of finished-dose products.
• API-to-finished-dose partnerships.

The competitive advantage is likely to come from manufacturing cost, regulatory reliability, and channel access rather than from composition-of-matter intellectual property.

What FDA regulatory pathway applies to new benztropine products?

A conventional tablet or injection that is pharmaceutically equivalent and bioequivalent to an approved reference product would generally be developed through an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must match the relevant strength, dosage form, route, labeling framework, and inactive-ingredient constraints.

A materially different dosage form, such as an orally disintegrating tablet or a new oral liquid, may require a 505(b)(2) application if the product cannot rely entirely on the ANDA pathway. The regulatory route depends on the formulation, reference product, clinical bridge, and extent of reliance on existing findings.

Important development considerations include:

• FDA inactive-ingredient precedent for the route and dosage form.
• Bioequivalence methodology for low-dose immediate-release tablets.
• IV or parenteral compatibility, sterility, and particulate requirements.
• Stability after opening for liquids and multidose containers.
• Human factors and device validation for prefilled syringes.
• Labeling of excipients with recognized safety or allergen concerns.

The FDA Inactive Ingredient Database is a key screening tool, but database presence does not replace product-specific justification, especially where the proposed maximum daily exposure or route differs from prior products (FDA, n.d.-b).

What patents protect benztropine mesylate?

Benztropine mesylate is an established generic drug with no meaningful current U.S. market position based on a live composition-of-matter patent. The original product and early formulation rights are long expired. Current competition is therefore governed primarily by generic approval status, manufacturing capability, supply contracts, and product-specific regulatory barriers.

The Orange Book remains relevant for checking listed patents, exclusivity, therapeutic-equivalence evaluations, and reference-product status. For an old generic such as benztropine mesylate, the principal commercial review is usually:

• Whether an approved reference listed drug remains available.
• Whether an ANDA applicant can establish bioequivalence.
• Whether any current patent or exclusivity listing applies to the specific product.
• Whether a formulation or device change creates a separate regulatory pathway.
• Whether manufacturing or supply agreements restrict access to a channel.

A conventional benztropine tablet is unlikely to support a commercially meaningful patent estate unless the sponsor develops a genuinely differentiated delivery system, device, manufacturing process, or formulation with unexpected performance. Any such patent would protect the improvement, not the underlying active ingredient.

When does benztropine mesylate lose exclusivity?

Benztropine mesylate lost meaningful market exclusivity decades ago. It is a mature generic active ingredient, and commercial entry is not blocked by a modern new-drug exclusivity period.

Potential entrants should distinguish among:

Exclusivity or barrier	Relevance to benztropine mesylate
Composition-of-matter patent	Expired for this mature active ingredient
New chemical entity exclusivity	Not relevant to current products
Orphan-drug exclusivity	Not a standard basis for the established products
Pediatric exclusivity	Not a current central commercial barrier
Formulation patent	Possible only for a new, defensible formulation
Device patent	Possible for a prefilled or specialized delivery system
Regulatory exclusivity	Depends on the specific new product and approval route
Manufacturing barrier	Highly relevant for sterile injection supply

The absence of active ingredient exclusivity increases price pressure. It also lowers the cost of entry for conventional tablets while increasing the importance of scale and quality systems.

Are there Paragraph IV challenges or biosimilar risks?

Paragraph IV litigation is generally not the principal risk for an old, off-patent generic product. A Paragraph IV certification becomes commercially relevant only when an applicant addresses a listed patent associated with a particular approved product. The underlying active ingredient itself does not create a current patent barrier.

Biosimilar risk does not apply. Benztropine mesylate is a small-molecule drug, not a biologic. Competition would come from additional ANDA applicants, authorized generics, private-label products, or reformulated products filed through an appropriate pathway.

The more realistic legal risks are:

• Patent disputes over a new orally disintegrating formulation.
• Device patent disputes over a prefilled syringe.
• Trade-secret disputes involving manufacturing processes.
• Trademark disputes involving product names and packaging.
• Contract disputes involving supply or private-label arrangements.

How strong is the patent estate for benztropine mesylate?

The patent estate for conventional benztropine mesylate products is weak from a market-exclusivity perspective. The opportunity is stronger as a formulation and supply-chain business than as a patent-protected pharmaceutical franchise.

Patent strength would improve if a sponsor could demonstrate:

• A new delivery profile with clinical utility.
• A stable liquid or suspension at a commercially useful concentration.
• A low-moisture orally disintegrating tablet with superior robustness.
• A ready-to-administer injectable device that reduces preparation errors.
• A manufacturing process with measurable yield, impurity, or stability advantages.
• A formulation that solves a documented compatibility or adherence problem.

Patent claims should be tied to measurable technical features, such as composition ranges, dissolution performance, particle characteristics, packaging conditions, or device configuration. Broad claims covering benztropine mesylate with routine excipients would face substantial validity and obviousness risk.

How does benztropine compare with competing anticholinergic products?

Benztropine competes clinically with other anticholinergic agents used for extrapyramidal symptoms and parkinsonian manifestations, including trihexyphenidyl and, in selected settings, diphenhydramine for acute dystonic reactions. The competitive position depends on route, institutional protocol, prescriber familiarity, and supply.

Product	Main commercial form	Competitive consideration
Benztropine mesylate	Tablet and injection	Established hospital and psychiatric use
Trihexyphenidyl hydrochloride	Primarily oral products	Oral alternative; different formulation and prescribing patterns
Diphenhydramine	Multiple oral and injectable products	Broad availability and acute-use familiarity
Amantadine	Oral products	Different mechanism and therapeutic positioning

Benztropine can compete effectively where hospitals need a recognized injectable product and where outpatient prescribers prefer a low-dose tablet. It is less attractive as a consumer-oriented product because anticholinergic adverse effects limit broad self-care positioning.

What manufacturing and intellectual-property barriers exist?

For tablets, the manufacturing barriers are modest but still material at commercial scale. The main requirements are low-dose blending, content uniformity, dissolution control, packaging, and reliable API sourcing.

For injection, the barriers are higher:

• Validated sterile manufacturing.
• Endotoxin and particulate control.
• Container-closure integrity.
• Sterility assurance.
• Stability under shipping conditions.
• Qualified suppliers for glass, elastomer, and packaging components.
• Batch-release testing.
• Hospital-compatible labeling and distribution.

The injectable product may offer the better supply-based opportunity because fewer manufacturers can produce sterile products consistently. That opportunity is operational rather than patent-based.

What revenue exposure and launch scenarios should investors evaluate?

Public revenue data for benztropine mesylate are not typically reported as a separate branded franchise because the product is generic and sold by multiple suppliers. Market modeling should therefore use product-level data such as:

• Annual prescription volume.
• Injectable unit demand.
• Average selling price by channel.
• Number of approved suppliers.
• Hospital contract coverage.
• Back-order and shortage history.
• API cost and sterile manufacturing cost.
• Gross margin by dosage form.

Three launch scenarios are commercially plausible:

Scenario	Product	Commercial profile
Base case	Conventional tablet	Low development risk, high price competition
Upside case	Preservative-free injectable with reliable supply	Better institutional differentiation and higher manufacturing barrier
Specialty case	Orally disintegrating tablet or oral liquid	Higher development cost, narrower but more defensible positioning

The strongest business case generally combines a conventional tablet for volume with a differentiated injectable or dysphagia-friendly product for margin protection.

Key Takeaways

• Benztropine mesylate is a mature, off-patent small-molecule generic.
• Conventional tablet entry is relatively accessible but exposed to price competition.
• Excipient selection should prioritize content uniformity, rapid dissolution, stability, and manufacturing reproducibility.
• Lactose-free, dye-free, and low-excipient formulations can support differentiation but rarely justify a premium alone.
• Preservative-free single-dose injection is the most credible hospital-focused opportunity.
• Orally disintegrating tablets and oral liquids could address dysphagia and dose-flexibility needs.
• Biosimilar risk does not apply, and Paragraph IV litigation is not the central market issue.
• A defensible patent strategy would need to cover a specific formulation, device, or manufacturing improvement.
• Revenue analysis requires product-level prescription, unit, pricing, and procurement data because benztropine sales are fragmented across generic suppliers.

FAQs About Benztropine Mesylate Formulation and Commercialization

Can benztropine mesylate be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could use mannitol, crospovidone, croscarmellose sodium, or other suitable excipients. Taste masking, moisture protection, tablet strength, and low-dose uniformity would be the principal development issues.

Is a lactose-free benztropine tablet commercially attractive?

It can be attractive as a differentiated generic, particularly for institutional formularies and patients avoiding lactose. The strongest commercial case pairs lactose removal with a clear operational advantage, such as improved supply, dysphagia-friendly administration, or dye-free labeling.

Does benztropine mesylate require a preservative in injectable form?

No universal rule requires a preservative. A single-dose preservative-free product can be developed if sterility, stability, container closure, and labeling requirements are satisfied. Multidose presentations may require a preservative strategy and additional in-use stability work.

Could a benztropine prefilled syringe support patent protection?

Potentially. Patentability would depend on the specific device configuration, formulation-device interaction, packaging, or administration feature. A routine transfer of an existing injectable solution into a conventional syringe would face a weaker patent position.

What is the most defensible commercial strategy for a new benztropine manufacturer?

A dual-product strategy is strongest: a low-cost immediate-release tablet for baseline volume and a differentiated preservative-free injectable or orally disintegrating product for institutional and specialty demand. The value would come from supply reliability, regulatory execution, and manufacturing quality rather than active-ingredient exclusivity.

References

1. DailyMed. (n.d.-a). Cogentin: Benztropine mesylate injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (n.d.-b). Benztropine mesylate tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.-b). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download

5. U.S. Food and Drug Administration. (n.d.-c). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

6. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary, USP 47-NF 42. U.S. Pharmacopeial Convention.